We have succesfully finished clinical part of phase II study with patients suffered from diabetes type II.
The aim of the study was to assess safety and efficacy of oral administration of IMP (different doses for each arm including placebo) accompanied to standard treatment, once daily for 14 consecutive days. 80 patients in total were enrolled. No drug related serious adverse events were recorded.
We are pleased to welcome a new member of the BRG medical expert team. Mr Jarosław Długołęcki, (M.D.) - doctor with extensive knowledge and 16-years’ experience in clinical studies at the international level.
We invite you to read our publication in the Biotechnology magazine - the largest industry portal in Poland, the latest information from the sectors: biotechnology, cosmetology, pharmacy and technologies.
We have started an interesting study with a promising antidiabetic drug. The drug is designed in the form of prolonged-action tablets, which action leads to increased insulin secretion.
